Clinical trial
Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for…
NCT00177307 · University of Pittsburgh, Other · Completed
Key facts
| NCT number | NCT00177307 |
|---|---|
| Title | Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer |
| Official title | Phase II Study of the A-ICOX Regimen Consisting of Bevacizumab (Avastinâ), Intermittent Dose Capecitabine (Xelodaâ) and Oxaliplatin (Eloxatinâ) in Patients With Untreated Advanced Colorectal Cancer |
| Lead sponsor | University of Pittsburgh, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab, Capecitabine, Oxaliplatin |
| Enrollment | 40 |
| Start date | Jan 1, 2005 |
| Primary completion | Feb 1, 2012 |
| Completion | Feb 1, 2012 |
| First posted | Sep 15, 2005 |
| Last update posted | Jul 12, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: